ARS Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
SPRY$3.15+12.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except par value and share amounts)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $50,817 | $70,971 |
| Short-term investments | 263,205 | 157,389 |
| Accounts receivable, net | 8,175 | — |
| Inventories | 5,212 | — |
| Prepaid expenses and other current assets | 6,886 | 3,366 |
| Total current assets | 334,295 | 231,726 |
| Long-term inventories | 5,307 | — |
| Right-of-use asset | 37 | 250 |
| Fixed assets, net | 1,029 | 574 |
| Intangible assets, net | 7,371 | — |
| Other assets | 3,114 | 638 |
| Total assets | $351,153 | $233,188 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (including related party amounts of $656 and $178, respectively) | $22,841 | $2,154 |
| Contract liability, current | 557 | — |
| Lease liability, current | 42 | 237 |
| Total current liabilities | 23,440 | 2,391 |
| Financing liability | 69,383 | — |
| Contract liability | 1,532 | — |
| Lease liability, net of current portion | — | 37 |
| Total liabilities | 94,355 | 2,428 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized at December 31, 2024 and 2023; 97,954,172 and 96,414,963 shares issued and outstanding at December 31, 2024 and 2023, respectively | 10 | 10 |
| Additional paid-in capital | 379,873 | 362,004 |
| Accumulated other comprehensive gain, net | 220 | 49 |
| Accumulated deficit | (123,305) | (131,303) |
| Total stockholders’ equity | 256,798 | 230,760 |
| Total liabilities and stockholders’ equity | $351,153 | $233,188 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.